Clinical Trials Sponsored by Vifor Pharma, Inc.

Total 2412 results

Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
Vifor Pharma, Inc.

Recruiting

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Hyperkalemia

United States, Israel
Vifor Pharma, Inc.

Terminated

FDDA Utilization Study (FDDAU)

Fatigue

Switzerland
Vifor (International) Inc.

Active, not recruiting

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (CARE-HK)

Heart Failure | Hyperkalemia

Spain, United States, United Kingdom, Italy, Switzerland, Belgium, Austria
Vifor (International) Inc.

Active, not recruiting

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients (ReliefCensus)

Chronic Kidney Disease-associated Pruritus

Germany, Italy, Portugal, Spain, Sweden, Switzerland, United Kingdom
Vifor (International) Inc.

Withdrawn

Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients (CKD)

Chronic Kidney Disease-associated Pruritus
Vifor (International) Inc.

Completed

Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Healthy

United Kingdom
Vifor (International) Inc.

Active, not recruiting

RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients (PORTRAY)

Chronic Kidney Disease

Germany
Vifor Pharma, Inc.
Syneos Health, LLC

Completed

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) (DIAMOND)

Hyperkalemia

United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
Vifor (International) Inc.
Fortrea

Completed

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity)

Sickle Cell Disease

United States, France, Greece, Lebanon, United Kingdom
Relypsa, Inc.

Completed

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) (OPAL)

Chronic Kidney Disease (CKD) | Hyperkalemia (HK)

United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine
Relypsa, Inc.

Completed

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease (AMBER)

Hyperkalemia | Resistant Hypertension

United States, Bulgaria, Croatia, Georgia, Germany, Hungary, South Africa, Ukraine, United Kingdom
Relypsa, Inc.

Completed

Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) (AMETHYST-DN)

Hypertension | Chronic Kidney Disease | Hyperkalemia

Croatia, Georgia, Hungary, Serbia, Slovenia
Relypsa, Inc.

Terminated

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Hyperkalemia

United States
Relypsa, Inc.

Completed

Patiromer With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Hyperkalemia

United States
Relypsa, Inc.

Completed

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

Heart Failure

Georgia, Slovenia
Vifor Pharma

Completed

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF)

Chronic Heart Failure | Iron Deficiency

Netherlands
Vifor Pharma

Completed

Study of Phosphate Levels in Patients With Chronic Kidney Disease (PA21)

Chronic Kidney Disease

United States, Switzerland, Romania, Croatia, Bulgaria, Germany, Czech Republic, Poland, Russian Federation
Vifor Pharma

Not yet recruiting

Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment (CARENFERPA)

Iron-deficiency
Vifor Pharma

Terminated

Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy (AOC-MM)

Iron-Deficiency Anemia

France, Greece
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Omeprazole and PA21

Healthy

United States
Vifor Pharma

Completed

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Atopic Dermatitis
Vifor Pharma

Completed

Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy (FID-CHEMO)

Iron-Deficiency Anemia

Germany, Sweden
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Losartan and PA21

Drug Interaction Potentiation

United States
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Warfarin and PA21

Drug Interaction Potentiation

United States
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Digoxin and PA21

Drug Interaction Potentiation

United States
Vifor Pharma

Completed

A Drug-Drug Interaction Study of Furosemide and PA21

Healthy

United States
Vifor Pharma

Terminated

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

Thrombocytosis | Iron-Deficiency Anemia

Austria
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Relypsa, Inc.
Medpace, Inc.

Completed

Evaluation of Patiromer in Heart Failure Patients (PEARL-HF)

Heart Failure | Hyperkalemia

United States, Czechia, Georgia, Germany, Poland, Russian Federation, Ukraine
Vifor (International) Inc.
Worldwide Clinical Trials; Cytel Inc.

Completed

Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF)

Heart Failure | Iron Deficiency

Poland, Georgia, Lebanon, Croatia, Argentina, Brazil, Israel, Italy, Netherlands, Romania, Singapore, Spain, Sweden, Ukraine, United Kingdom
Vifor Pharma
Parexel

Completed

Maintenance Treatment of Iron Deficiency in IBD Patients (FER-IBD-MAIN)

Iron Deficiency | Inflammatory Bowel Disease

Russian Federation
Vifor (International) Inc.
Tigermed Consulting Co., Ltd

Completed

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

Iron Deficiency Anemia

China
Vifor (International) Inc.
Labcorp Corporation of America Holdings, Inc

Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia (VITHAL)

Beta-Thalassemia | Non-transfusion-dependent Thalassemia

Greece, Israel, Italy, Lebanon, Thailand
Yale University
Vifor Pharma; Relypsa, Inc.

Active, not recruiting

Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists (PROMPT-MRA)

Heart Failure With Reduced Ejection Fraction

United States
Göteborg University
Vifor Pharma

Completed

Omega 3/6 Fatty Acids for Reading in Children

Reading Ability
Hospital Aleman
Vifor Pharma

Completed

Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)

Iron Deficiency | Anaemia

Argentina
Vifor Pharma
SGS S.A.

Completed

Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age (Prefer)

Iron Deficiency

Austria
Göteborg University
Vifor Pharma

Completed

Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents

ADHD | Reading/Writing Disorder
Duke University
Vifor Pharma

Completed

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

End Stage Renal Disease | Hyperkalemia

United States
Mahidol University
Vifor Pharma

Completed

Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment (EIVF)

Anemia | Pregnancy Complications

Thailand
Medical University of Vienna
Vifor Pharma, Inc.

Recruiting

Iron Status in Female Infertility and Recurrent Miscarriage

Infertility | Iron-deficiency | Recurrent Miscarriage

Austria
Turku University Hospital
Vifor Pharma

Recruiting

Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery (PREFER-CABG)

Coronary Artery Disease | Postoperative Complications | Aortic Valve Stenosis | Aortic Aneurysm, Thoracic | Mitral Valve Disease

Finland
University of Zurich
Vifor Pharma

Terminated

Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery

Iron Deficiency Anemia

Switzerland
Vifor Pharma
Parexel; ClinStar, LLC

Completed

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR (FER-IBD-COR)

Anemia | Crohn's Disease | Ulcerative Colitis | Iron Deficiency | Inflammatory Bowel Disease | Iron-Deficiency Anemia

Austria
Vifor Pharma
ICON Clinical Research; American Regent, Inc.

Completed

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (FIND-CKD)

Chronic Kidney Disease | Iron Deficiency Anaemia

United Kingdom, United States, Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey
Vifor Pharma
ICON Clinical Research

Completed

A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency (CONFIRM-HF)

Chronic Heart Failure | Iron Deficiency

Poland, Russian Federation
University Hospital Muenster
Vifor Pharma

Terminated

Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery (PRIVIRON)

Anemia | Orthopedic Surgery | High Risk of Blood Loss

Germany
GWT-TUD GmbH
Vifor Pharma

Completed

Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency (CLEVER)

Type 2 Diabetes Mellitus | Iron Deficiency

Germany
Vifor Pharma
Socar Research SA

Terminated

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure (EFFICACY-HF)

Chronic Heart Failure | Iron Deficiency Anemia | Iron Deficiency | Anaemia

France, Netherlands, Denmark, Germany, Israel

Clinical Trials Sponsored by Vifor Pharma, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations